Department Researches & Publications

Department of Pharmaceutical Organic Chemistry

Research

Our researches Plan:

1- Development, study in depth of pharmaceutical organic chemistry and illustration of its synthetic, mechanistic, and industrial applications.

2- Design and synthesis of different classes of compounds such as: Triazoles, benzimidazoles, piperazinedione and thiadiazine derivatives and others A special focus on xanthine and pyridazinone derivatives

3- Structural elucidation of the target compounds utilizing: IR,1H-NMR, MS in addition to elemental analysis Optical Rotation

4- Biological screening: Antimicrobial: antibacterial, antifungal and antituberculosis in addition to anthlemintic activity. Anti-inflammatory, analgesic, antipyretic activities and ulcerogenicity determination. Cardiotonic and hypotensive activities. Hypoglycemic activity. Anticonvulsant activity.

5- Other titles in consideration: Synthesis of new dendimers of potential biological activity. Applications of photochemical reactions for synthesis of certain organic compounds of potential biological activity. Synthesis of some antineurodegenerative compounds. Synthesis of certain nucleosides of potential biological activity. Synthesis of certain adenine derivatives of possible antiviral activity.

#	Title	Research Year
11	Covalent small-molecule inhibitors of SARS-CoV-2 Mpro: Insights into their design, classification, biological activity, and binding interactions	2024
12	Design and synthesis new dihydropyrimidine derivatives with cytotoxic effect as dual EGFR/VEGFR-2 inhibitors	2024
13	Design and synthesis new indole-based aromatase/iNOS inhibitors with apoptotic antiproliferative activity	2024
14	Design and synthesis of new 1, 2, 4-oxadiazole/quinazoline-4-one hybrids with antiproliferative activity as multitargeted inhibitors	2024
15	Design and synthesis of New dihydropyrimidine/sulphonamide hybrids as promising anti-inflammatory agents via dual mPGES-1/5-LOX inhibition	2024
16	Design and synthesis of novel quinoline-ester/-amide derivatives as potent antiproliferative agent targeting EGFR and BRAFV600E kinases	2024
17	Design, synthesis and mechanistic anticancer activity of new acetylated 5-aminosalicylate-thiazolinone hybrid derivatives	2024
18	Design, synthesis, and antiproliferative activity of new 1, 2, 3-triazole/quinazoline-4-one hybrids as dual EGFR/BRAF V600E inhibitors	2024
19	Design, synthesis, and antiproliferative activity of new indole/1,2,4-triazole/chalcone hybrids as EGFR and/or c-MET inhibitors	2024
20	Design, synthesis, and apoptotic antiproliferative action of new 1,2,3-triazole/1,2,4-oxadiazole hybrids as dual EGFR/VEGFR-2 inhibitors	2024